STOK - Stoke Therapeutics: Positive Dravet Data Sends Shares Soaring One For The Watchlist

2024-04-04 01:12:23 ET

Summary

• Stoke Therapeutics' stock has surged after positive data from studies of its lead drug candidate, STK-001, in children with Dravet syndrome.
• Dravet syndrome is a severe form of epilepsy that causes multiple seizure types and developmental disabilities.
• Stoke's STK-001 demonstrated substantial reductions in convulsive seizure frequency and improvements in cognition and behavior in patients.
• An approval seems likely, however, investors will need to be patient. An opportunity in ophthalmology and a partnership with Acadia Pharmaceuticals add further value to the company.

Investment Overview

Stoke Therapeutics' ( STOK ) stock has been soaring in response to the positive data the company shared from two open-label Phase 1/2a studies and two open-label extension ("OLE") studies of its lead drug candidate STK-001 in children and adolescents ages 2 to 18 with Dravet syndrome, on March 25th this year....

For further details see: